Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alvogen Acquires Naprelan from Shionogi | Contract Pharma

What are you searching for?

Sign in
Breaking News

Alvogen Acquires Naprelan from Shionogi

Gains exclusive rights in the U.S. to naproxen product

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alvogen Pharma US, Inc. has acquired from Shionogi Inc., exclusive rights to commercialize Naprelan (naproxen sodium) controlled-release tablets, 375 mg, 500 mg, and 750 mg, in the U.S. Naprelan is indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis and acute gout, as well as the relief of mild to moderate pain, and the treatment of primary dysmenorrhea. The product will be marketed by Alvogen’s subsidiary, Almatica Pharma, Inc.
 
Alvogen also acquired all rights and interest in the NDA for Naprelan from Stat-Trade, Inc. According to IMS Health data, Naprelan had annual U.S. sales of $58 million in 2012.
 
“Alvogen’s acquisition of Naprelan delivers on yet another strategic objective by further strengthening and diversifying our growing branded portfolio in the U.S. market,” said Darren Alkins, president, Alvogen Americas.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters